Kaitlyn Bader, Assistant Managing Editor

Arash Mostaghimi, MD, MPH, MPA, provides insights into what clinicians need to know about deuruxolitinib for severe AA.

Gooderham reviews key highlights from EADV 2024 on the ADjoin long-term extension trial for patients with moderate to severe AD.

Kilian Eyerich, MD, PhD, shares insights into an EADV 2024 presentation on upadacitinib’s ability to achieve almost total skin clearance in the head and neck regions with minimal effect on quality of life.

As conference season approaches the last few months of the year, catch up on highlights from NP & PA conferences, including Fall Clinical for PAs and NPs and SDPA Summer.

Catch up on eczema advancements throughout the year, including news on contact dermatitis, chronic hand eczema, and more.

Catch up on the latest news on prurigo nodularis advancements in 2024.

Dermavant’s sNDA for tapinarof cream 1% for AD is still under review with the FDA.

In case you missed it, this week we had news about phase 2 initiation of EVO756 for chronic inducible urticaria, IBI363's Fast Track Designation for advanced melanoma, Arcutis' enrollment of the last patient in ARQ-255 trial for alopecia areata, and more.

The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.

This week’s collection of the latest dermatologic studies includes the implementation of an action plan for patients with atopic dermatitis, early childhood eczema and the risk of allergic multicomorbidities, and more.